Chronotherapy

From Glioblastoma Treatments
Jump to navigationJump to search
Property Information
Drug Name Chronotherapy with Temozolomide (TMZ)
FDA Approval Yes (as part of standard glioblastoma treatment)
Used for Glioblastoma Multiforme (GBM)
Clinical Trial Phase Research ongoing
Clinical Trial Explanation Not specified
Common Side Effects Increased side effects when administered in the morning; however, these are generally manageable with other therapies.
OS without 13.5 months for general cases, 19.5 months for patients with MGMT methylated tumors.
OS with 17 months for general cases, 25.5 months for patients with MGMT methylated tumors when administered in the morning.
PFS without Standard progression statistics for GBM.
PFS with Improved in morning dosing, exact data still under investigation.
Usefulness Rating 4
Usefulness Explanation Chronotherapy with TMZ could significantly extend survival times, particularly for patients with MGMT methylated tumors.
Toxicity Level Comparable to standard TMZ treatments, but timing affects management of side effects.
Toxicity Explanation Morning administration of TMZ shows potential for increased efficacy, with manageable increases in side effects.

Notes: Emerging evidence suggests that adjusting the timing of TMZ to morning administration could extend overall survival times for GBM patients, particularly those with MGMT methylated tumors. This approach aligns with the chronotherapy concept, which utilizes the body's circadian rhythms to optimize drug efficacy and minimize toxicity.

Links: https://medicine.wustl.edu/news/chemo-for-glioblastoma-may-work-better-in-morning-than-evening/, https://www.mdpi.com/2072-6694/13/11/2659

From Ben Williams Book: Not specified

Loading comments...